(Avishek Das/Getty Images)

Hims rises on revenue beat, discloses it’s again in partnership talks with Novo

Hims also disclosed on Monday that it’s in talks with Novo Nordisk to make the drugmaker’s weight-loss drugs available on its platform. Last time, that didn’t go so well.

J. Edward Moreno

11/3/25 4:14PM

Hims & Hers reported third-quarter earnings results that missed Wall Street estimates but revenue that blew expectations out of the water. The company also said it’s talking with Novo Nordisk again about a potential deal to distribute its branded weight-loss drugs.

The company reported diluted earnings per share of $0.06, less than the $0.09 analysts polled by FactSet were expecting. Hims also reported $598.9 million in sales, significantly more than the $580.2 million the Street was penciling in.

The company narrowed its full-year revenue guidance to about $2.35 billion from between $2.3 billion and $2.4 billion.

Hims also disclosed on Monday that it’s in talks with Novo to make its branded weight-loss drugs available on the telehealth company’s platform. The two previously had a partnership that ended abruptly in June after Novo accused Hims of “illegal mass compounding and deceptive marketing.”

Hims has been looking for ways to spark sales growth as its core sexual health business slows down and its ability to sell weight-loss treatments remains on shaky ground. In recent months, the company has introduced testosterone treatments and menopause regimens, as well as GLP-1 “micro-dosing” options.

Additionally, the company disclosed that it’s continuing to explore international expansion “in key markets including Brazil, the U.K., Germany, and Australia.” Earlier this year, the company acquired a European peer, Zava, for $265.7 million, and announced plans to expand to Canada in 2026 to offer generic versions of Novo’s weight-loss shot.

Hims said it plans to launch “comprehensive lab testing capabilities in the near future.” That will support its upcoming “longevity” specialty as well as its injectable testosterone offerings, both of which it says are coming next year.

Luke Kawa

7/13/26

Meet the newly public, Bezos-backed company that’s recreating the sun and stars

General Fusion CEO Greg Twinney spoke with Sherwood News from the Nasdaq during the stock’s first day of trading.

J. Edward Moreno7/7/26

SpaceX gets a wave of bullish ratings from Wall Street analysts

SpaceX received more than a dozen positive analyst calls on Tuesday — including from major Wall Street banks — as they initiate coverage on Elon Musk’s space and AI company.

SpaceX went public on June 12 at a $2.2 trillion valuation, the largest debut in history. While the company hasn’t yet posted a profit, it seems to have convinced Wall Street that it will get there and grow its valuation on the way.

Of the at least 17 analysts that gave a rating on Tuesday, all but one gave it a “buy” or “outperform” rating. MoffettNathanson was "neutral."

The ratings come as SpaceX joined the Nasdaq 100 index, a benchmark tech-heavy basket of companies that underpins millions of portfolios. The inclusion adds built-in demand for the stock from index funds and ETFs.

Still, SpaceX fell more than 5% on Tuesday amid a broader sell-off, and is currently effectively flat from its opening price of $150 a share.

Luke Kawa

7/2/26

US job growth falls far short of estimates in June; unemployment rate unexpectedly dips to 4.2%

Job growth was 57,000. Analysts foresaw job growth of 113,000; prediction markets were more optimistic, looking for job growth above 125,000 but below 150,000.

Floridians Seek Employment Opportunities At Job Fair In Sunrise

Luke Kawa

7/1/26

Meta surges on report it’s starting a cloud business to sell excess AI compute

The story of the hyperscalers in 2026 has largely been “the beatings will continue until the cash flow outlook improves;” this could help change the story for Meta. Or not.

Meta CEO Mark Zuckerberg visits U.S. Capitol for Senate meetings

Paige Oamek6/30/26

Nike sinks to lowest level since 2014 after warning of “challenged” sales environment in Q4 report

Did Nike do it?

Investors had a mixed reaction after the global sports apparel company reported its fourth quarter earnings on Tuesday after the bell. Shares initially rose 5% as Nike beat out Wall Street expectations amid a hefty tariff refund bonus. However, the stock then sank to its lowest level since August 2014 in postmarket trading.

Here are the Q4 numbers:

Revenue of $11.0 billion (estimate: $10.8 billion).
Adjusted earnings per share of $0.20 (estimate: $0.12).

Ahead of this report, Nike warned that results would be flattered by a one-time tariff refund (now estimated at roughly $0.52 per share for the bottom line). That gave the company an extra cushion in snapping its streak of seven quarters of year-over-year profit declines.

Over the past year, the company had been punished by tariffs on imported goods, stagnant consumer spending, and increasing competition from other footwear brands like New Balance, Adidas, and Hoka.

Outgoing CFO Matthew Friend deemed it an “increasingly challenging operating environment, where sell-through remains challenged.”

Hims rises on revenue beat, discloses it’s again in partnership talks with Novo

More Markets

SpaceX gets a wave of bullish ratings from Wall Street analysts

Nike sinks to lowest level since 2014 after warning of “challenged” sales environment in Q4 report

Latest Stories